Posted by AGORACOM-JC
at 7:55 AM on Monday, January 25th, 2021
Received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO.
MONTREAL , Jan. 25, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO. “Redesca™ has a long and strong history of safety and efficacy with more than 8 years of proven in-market data internationally. Redesca™ will be available across Canada and Valeo intends to pursue discussions for the inclusion of Redesca on all other provincial formularies. Valeo is planning to launch Redesca™ during the first half of 2021.”
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWHs are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
Posted by AGORACOM-JC
at 7:14 AM on Monday, January 18th, 2021
Frederic Fasano named President and COO
Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
Posted by AGORACOM-JC
at 12:14 PM on Thursday, January 14th, 2021
Commercial launch to impact first half 2021 revenue
$30 million forecasted annual peak sales
8 years of proven in-market safety Internationally
Low molecular weight heparin increasingly used to prevent COVID-19 driven complications
“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.
According to the newsletter, Hesperidin has recently attracted the attention of researchers, because it binds to key proteins of SARS-CoV-2 1 . This may interfere with viral entry into host cells 4 .
In Wu et. al (2020 ), the screening of 1066 natural substances with potential antiviral effect, plus 78 antiviral drugs already known in the literature for their binding to SARS-CoV-2 proteins, Hesperidin was the only compound that could target the binding interface between viral Spike proteins and ACE-2 human receptors 2 .
Hesperidin can also bind to 3CLpro – the main protease responsible for the cleavage of SARS-CoV-2 peptides into functional units for virus replication and packaging within the host cells 1,3 . By doing so, it may help against COVID-19 viral replication 4 .
Posted by AGORACOM
at 8:32 AM on Tuesday, December 29th, 2020
Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo“), a Canadian pharmaceutical company, announced today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States.
“We are pleased to have secured DTC eligibility to facilitate the trading of our common shares for U.S investors and brokerage firms. This will allow for faster execution and improved liquidity which will help with broadening our investor base”, said Steve Saviuk, President and CEO.
DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.
Valeo has also engaged Native Ads Inc. (“Native Ads”), a full service advertising agency, to provide digital media services, vendor management, marketing and data analytics services to Valeo and has budgeted USD $250,000 for such services over an expected 12 month period. Neither Native Ads or any of its directors and officers own any securities in Valeo.
About Valeo Pharma
Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.comand follow us on LinkedIn and Twitter.
Posted by AGORACOM-JC
at 6:00 PM on Tuesday, December 22nd, 2020
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight. Saviuk agreed and gave the following 3 reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization’s (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when COVID-19 infection is suspected.
The Canadian market for LMWH was already at a healthy $200M + per year when Valeo started down the Redesca path 4 years ago. Now it gets the added kicker of Redesca being a first line of defense to fight COVID-19.
Now you have it. That’s the Valeo story as it applies to Redesca. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
